Bioisosterism: A rational approach in drug design

Chemical Reviews

Volumn 96, Issue 8, 1996, Pages 3147-3176

  Patani, George A ^a,b   LaVoie, Edmond J ^a,c,d,e,f,g  

^a RUTGERS UNIVERSITY   (United States)

^b MANGALORE UNIVERSITY   (India)

^c FORDHAM UNIVERSITY   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f AMERICAN HEALTH FOUNDATION   (United States)

^g RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7744243992     PISSN: 00092665     EISSN: None     Source Type: Journal    
DOI: 10.1021/cr950066q     Document Type: Article

References (191)

1. Martin, Y. C. A Practitioner's Perspective of the Role of Quantitative Structure-Activity Analysis in Medicinal Chemistry. J. Med. Chem. 1981, 24,229-237.
2. Friedman, H. L. Influence of Isosteric Replacements upon Biological Activity. NASNRS 1951, 206, 295-358.
3. Thornber, C. W. Isosterism and Molecular Modification in Drug Design. Chem. Soc. Rev. 1979, 8, 563-580.
4. Lipinski, C. A. Bioisosterism in Drug Design. Annu. Rep. Med. Chem. 1986, 27, 283-291.
5. Burger, A. Isosterism and Bioisosterism in Drug Design. Prog. Drug Res. 1991, 37, 287-371.
6. Hansch, C. The Physicochemical Approach to Drug Design and Discovery. Drug Dev. Res. 1981, 1, 267.
7. Langmuir, I. Isomorphism, Isosterism and Covalence. J. Am. Chem. Soc. 1919, 41, 1543-1559.
8. Seifriz, W. Pathogenicity and Isosterism. Science 1948, 707, 15-16.
9. Grimm, H. G. Structure and Size of the Non-metallic Hydrides Z. Electrochem. 1925, 31, 474-480.
10. Grimm, H. G. On the Systematic Arrangement of Chemical Compounds from the Perspective of Research on Atomic Composition; and on Some Challenges in Experimental Chemistry. Naturwissenschaften 1929, 17, 557-564.
11. Erlenmeyer, H.; Leo, M. On Pseudoatoms. Helv. Chim. Acta 1932, 15, 1171-1186.
12. Burger, A. In Medicinal Chemistry, 3rd ed.; Burger, A., Ed.; Wiley-Interscience: New York, 1970; pp 64-80.
13. Pauling, L. In The Nature of the Chemical Bond, 2nd ed.; Cornell University Press; New York, 1940; pp 189.
14. Zhang, W; Koehler, K. F.; Harris, B.; Skolniok, P.; Cook, J. M. Synthesis of Benzo-Fused Benzodiazepines Employed as Probes of the Agonist Pharmacophore of Benzodiazepine Receptors. J. Med. Chem. 1994, 34, 745-757.
15. Phillipps. G. H.; Bailey, E. J.; Bain, B. M.; Borella, R. A.; Buckton, J. A.; Clark, J. C.; Doherty, A. E.; English, A. F.; Fazakerley, H.; Laing, S. B.; Lane-Allman, E.; Robinson, J. D.; Sanford, P. E.; Sharatt, P. J.; Steeples, I. P.; Stonehouse, R. D.; Williamson, C. Synthesis and Structure-Activity Relationships in a series of Anti-inflammatory Corticosteroid Analogues, Halomethyl Androstane-17β-Carbothionates and 17β-Carboselenoates. J. Med. Chem. 1994, 37, 3717-3729.
16. Tonelli, G.; Thibault, L.; Ringler, I. A Bio-assay for the Concomitant Assessment of the Antiphlogistic and Thymolytic Activities of Topically Applied Corticoids. Endocrinology 1965, 77, 625-634.
17. Skagerberg, B.; Bonelli, D.; Clementi, S.; Cruciani, G.; Ebert, C. Principal Properties for Aromatic Substituents. A Multivariate Approach for Design in QSAR. Quant. Struct.-Act. Relat. 1989, 8, 32-38.
18. Elguero, J.; Marzin, C.; Katritzky, A. R.; Linda, P. In Advances in Heterocyclic Chemistry; Katritzky, A. R., Boulton, A. J., Eds.; Academic Press Inc.: New York, 1976; Suppl. 1.
19. Fusco, T.; Chiavarelli,S.; Palazzo, G.; Bovet, D. Research on Synthetic Curare. Part II Arylalkyl Derivatives with Two Quaternary Ammonium Functional Groups. Gazz. Chim. Itol. 1948, 78, 951.
20. Kelley, J. L.; Mclean, Ed. W.; Ferris, R. M.; Howard, J. L. Benzodiazepine Receptor Binding Activity of 6,9-Disubstituted Purines. J. Med. Chem. 1989, 32, 1020-1024.
21. Bennett, L. L.; Simpson, L., Jr.; Golden, J.; Barker, T. L. The Primary Site of Inhibition by 6-Mercaptopurine on the Purine Biosynthetic Pathway in Some Tumors in Vivo. Cancer Res. 1963, 23, 1574-1580.
22. LePage, G. A.; Junga, I. G.; Bowman, B. Biochemical and Carsinostatic Effects of 2′-Deoxythioguanosine. Cancer Res. 1964, 24, 835-840.
23. Atwal, K. S.; Rovnyak, G. C.; Kimball, D. S.; Floyd, D. M.; Moreland, S.; Swanson, B. N.; Gougoutas, J. K.; Schwartz, J.; Smillie, K. M.; Malley, M. F. Dihydropyrimidine Calcium Channel Blockers 2. 3-Substituted-4-aryl-1,4 dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyrimidines. J. Med. Chem. 1990, 33, 2629-2635.
24. Hine, J. In Physical Organic Chemistry; Hine, J., Ed.; McGraw Hill Book Co. Inc.: New York, 1962: p 28.
25. Kimmey, M. B. NSAIDs, Ulcers and Prostaglandins. J. Rheumatol. 1992, 19 (Suppl. 36), 68-73.
26. Peskar, B. M. The Synthesis of Prostaglandins by Human Gastric Mucosa and its Modification by Drugs. Biochem. Biophys. Acta 1977, 487, 307-314.
27. Unangst, P. C.; Connor, D. T.; Cetenko, W. A.; Sorenson, R. J.; Kostlan, C. R.; Sircar, J. C.; Wright, C. D.; Schrier, D. J.; Dyer, R. D. Synthesis and Biological Evaluation of 5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene] oxazoles, -thiazoles, and -imidazoles: Novel Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors with Anti-inflammatory Activity. J. Med. Chem. 1994, 37, 322-328.
28. Vane, J. R. Inhibition of Prostaglandin Synthesis as a mechanism of Action of Aspirin-like Drugs. Nature (New Biol.) 1971, 231, 232-235.
29. Huheey, J. E. The Electronegativity of groups. J. Phys. Chem. 1965, 69, 3284-3291.
30. Fournie-Zaluski, M. C.; Coric, P.; Turcaud, S.; Rousselet, N.; Gonzalez, W; Barbe, B.; Pham, I.; Jullian, N.; Michel, J. B.; Roques, B. P. New Dual Inhibitors of Neutral Endopeptidase and Angiotensin-Converting Enzyme: Rational Design, Bio-availability, and Pharmacological Responses in Experimental Hypertension. J. Med. Chem. 1994, 37, 1070-1083.
31. Bott, G.; Field, L.; Sternhell, S. Steric effects. A Study of a Rationally Designed System. J. Am. Chem. Soc. 1980, 102, 5618-5626.
32. 6-Alkylguanine-DNA Alkyltransferase. J. Med. Chem. 1995, 38, 359-365.
33. Takemoto, T.; Eda, M.; Okada, T.; Sakashita, H.; Matzno, S; Gohda, M.; Ebisu, H.; Nakamura, N.; Fukaya, C.; Hihara, M.; Eiraku, M.; Yamanouchi, K.; Yokoyama, K. Novel Potassium Channel Openers. Synthesis and Pharmacological Evaluation of New N-(Substituted-3-pyridyl)-N′-alkylthioureas and Related Compounds. J. Med. Chem. 1994, 37, 18-25.
34. Pendergast, W.; Johnson, J. V.; Dickerson, S. H.; Dev, I. K.; Duch, D. S.; Ferone, R.; Hall, W. R.; Humphreys, J.; Kelly, J. M.; Wilson, D. C. Benzoquinazoline Inhibitors of Thymidylate Synthase: Enzyme Inhibitory Activity and Cytotoxicity of some 3-Amino- and 3-Methylbenzo[f]quinazolin-1(2H)-ones. J. Med. Chem. 1993, 36, 2279-2291.
35. Roberts, D. An Isotopic Assay for Thymidylate Synthethase. Biochemistry 1966, 5, 3546-3548.
36. Dev, I. K.; Yates, B. B.; Atashi, J.; Dallas, VV. S. Catalytic Role of Histidine 147 in Escherischia Coli Thymidylate Synthase. J. Biol. Chem. 1989, 264, 19132-19137.
37. Saunders, J.; Freedman, S. B. The Design of Full Agonists for the Cortical Muscarinic Receptor. Trends Pharmacol. Sci. 1989, (Suppl.), 70-75.
38. Rogers, E. F.; Brown, H. D.; Rasmussen, I. M.; Heal, R. E. The Structure and Toxicity of DDT Insecticides. J. Am. Chem. Soc. 1953, 75, 2991-2999.
39. Büchi, V. J.; Bruhin, H. K.; Perlia, X. Relations Between the Physicochemical Properties, the Chemical Reactivity, and the Local Anesthetic Activity of 4-Substituted Diethylaminoethyl Esters of Benzoic Acid. Arzneim. Forsch. 1971, 7, 1003-1017.
40. Ahmad, A.; Mond, J. J. 8-Hydroxyguanosine and 8-Methoxyguanosine Possess Immunostimulating Activity for B Lymphocytes. Cell. Immunol. 1985, 94, 276-280.
41. Li, X; Singh, S. M.; Cote, J.; Laplante, S.; Veilleux, R.; Labrie, F. Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17β-carboxamides as 5α-Reductase Inhibitors and Anti-androgens. J. Med. Chem. 1995, 38, 1456-1461.
42. Wrobel, J.; Millen, J.; Sredy, J.; Dietrich, A.; Kelly, J. M.; Gorham, B. J.; Sestanj, K. Orally Active Aldolase Reductase Inhibitors Derived from Bioisosteric Substitutions on Tolrestat. J. Med. Chem. 1989, 32, 2493-2500.
43. Bonnet, P. A.; Robins, R. K. Modulation of Leukocyte Genetic Expression by Novel Purine Nucleoside Analogues. A New Approach to Antitumor and Antiviral Agents. J. Med. Chem. 1993, 36, 635-653.
44. Walsh, D. A.; Franzyshen, S. K.; Yanni, J. M. Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)propyl] piperidines and Structurally Related Compounds. J. Med. Chem. 1989, 32, 105-118.
45. Wheland, G. W. In Resonance in Organic Chemistry; Wiley: New York, 1955; pp 695-784.
46. Michne, W. F.; Schroeder, J. D.; Guiles, J. W.; Treasurywala, A. M.; Weigelt, C. A.; Stansberry, M. F.; McAvoy, E.; Shah, C. R.; Baine, Y.; Sawutz, D. G.; Miller, P. B.; Stankunas, B. M.; Reid, J.; Bump, E.; Schlegel, D. Novel Inhibitors of the Nuclear Factor of Activated T Cells (NFAT)-Mediated Transcription of β-Galactosidase: Potential Immunosuppressive and Antiinflammatory Agents. J. Med. Chem. 1995, 38, 2557-2569.
47. Counsell, R. E.; Klimstra, P. D.; Nysted, L. N.; Ranney, R. E. Hypocholesterolemic Agents. V. Isomeric Azacholesterols. J. Med. Chem. 1965, 8, 45-48.
48. Lide, D. R. In Handbook of Chemistry and Physics, 71st ed.; CRC Press Inc.: Boca Raton, 1990; pp 9-5.
49. Saeed, A.; Mcmillin, J. B.; Wolkowicz, P. E.; Brouillette, W. J. 3-Amino-5,5-dimethylhexanoic Acid. Synthesis, Resolution, and Effects on Carnitine Acyltransferases. J. Med. Chem. 1994, 37, 3247-3251.
50. Yamakawa, T.; Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Retinobenzoic Acids. 5. Retinoidal Activities of Compounds Having a Trimethylsilyl or Trimethylgermyl Groups in Human Promyelocytic Leukemia Cell HL-60. J. Med. Chem. 1990, 33, 1430-1437.
51. Hunt, R.; Renshaw, R. R. On Some Effects of Arsonium, Stibonium, Phosphonium and Sulphonium Compounds on the Autonomic Nervous System. J. Pharmacol. Exp. Ther. 1925, 25, 315-355.
52. Grisar, J. M.; Marciniak, G.; Bolkenius, F. N.; Verne-Mismer, J.; Wagner, E. R. Cardioselective Ammonium, Phosphonium and Sulfonium Analogues of α-Tocopherol and Ascorbic Acid That Inhibit in Vitro and ex Vivo Lipid Peroxidation and Scavenge Superoxide Radicals. J. Med. Chem. 1995, 38, 2880-2886.
53. Eydoux, F.; Chlenov, M. A.; Réglier, M. Synthesis of Indane Derivatives as Mechanism-Based Inhibitors of Dopamine β-Hydroxylase. Bioorg. Med. Chem. Lett. 1995, 5, 941-944.
54. Alousi, A. A.; Edelson, J. Amrinone. In Pharmacological and Biochemical Properties of Drug Substances; Goldberg, M. E., Ed.; American Pharmaceutical Association: Washington, DC, 1982; Vol. 3, pp 120-147.
55. Alousi, A. A.; Stankus, G. P.; Stuart, J. C.; Walton, L. H. Characterization of the Cardiotonic Effects of Milrinone, a New and Potent Cardiac Bipyridine, on Isolated Tissues From Several Animal Species. J. Cardiovasc. Pharmacol. 1983, 5, 804-811.
56. Singh, B.; Lesher, G. Y. Synthesis of Analogs of Amrinone: 4-(3,4-Disubstitutedphenyl)pyridines and Derivatives Thereof. J. Heterocycl. Chem. 1991, 28, 933-937.
57. Singh, B.; Bacon, E. R.; Robinson, S.; Fritz, R. K.; Lesher, G. Y.; Kumar, V.; Dority, J. A.; Reuman, M.; Kuo, G.; Eissenstat, M. A.; Pagani, E. D.; Bode, D. C.; Bentley, R. G.; Connell, M. J.; Hamel, L. T.; Silver, P. J. Novel cAMP PDE III Inhibitors: Imidazo [4,5-b] pyridin-2(3H)-ones and Their Analogs. J. Med. Chem. 1994, 37, 248-254.
58. Brewer, M. D.; Burgess, M. N.; Dorgan, R. J. J.; Elliott, R. L.; Mamalis, P.; Manger, B. R.; Webster, R. A. B. Synthesis and Anthelmintic Activity of a Series of Pyrazino [2,1-a][2]benzazepine Derivatives. J. Med. Chem. 1989, 32, 2058-2062.
59. Forest, M.; Lahouratate, P.; Martin, M.; Nadler, G.; Quiniou, M. J.; Zimmermann, R. G. A Novel Class of Cardiotonic Agents: Synthesis and Biological Evaluation of 5-Substituted 3,6-Dihydrothiadiazin-2-ones with Cyclic AMP Phosphodiesterase Inhibiting and Myofibrillar Calcium Sensitizing Properties. J. Med. Chem. 1992, 35, 163-172.
60. Ahluwalia, G. S.; Jayaram, H. N.; Cooney, D. A. In Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy, Martinus Nijhoff Publishers: Boston, 1987; Chapter 3.
61. Franchetti, P.; Cristalli, G.; Grifantini, M.; Cappellacci, L.; Vittori, S.; Nocentini, G. Synthesis and Anti-tumor Activity of 2β-D-Ribofuranosyloxazole-4-carboxamide. J. Med. Chem. 1990, 33, 2849-2852.
62. Lakhan, R.; Ternai, B In Advances in Heterocyclic Chemistry; Katritzky, A. R., Boulton, A. J., Ed.; Academic Press: New York, 1974; Vol. 17, p 173.
63. Uno, T.; Kondo, H.; Inoue, Y.; Kawata, Y.; Sotomura, M.; Iuchi, K.; Tsukamoto, G. Synthesis of Anti-microbial Agents 3. Syntheses and Antibacterial Activities of 7-(4-Hydroxypiperazin-1-yl) quinolones. J. Med. Chem. 1990, 33, 2929-2932.
64. Yoshino, K.; Kohno, T.; Morita, T.; Tsukamoto, G. Organic Phosphorus Compounds. 2. Synthesis and Coronary Vasodilator Activity of (Benzothiazolylbenzyl) phosphonate Derivatives. J. Med. Chem. 1989, 32, 1528-1532.
65. Dunn, D. L.; Scott, B. S.; Dorsey, E. D. Analysis of Pilocarpine and Isopilocarpine in Ophthalmic Solutions By Normal-Phase High-Performance Liquid Chromatography. J. Pharm. Sci. 1981, 70, 446.
66. Sauerberg, P.; Chen, J.; WoldeMussie, E.; Rapoport, H. Cyclic Carbamate Analogues of Pilocarpine. J. Med. Chem. 1989, 32, 1322-1326.
67. Sun, Q.; Gatto, B.; Yu, Chiang, Liu, A.; Liu, L. F.; LaVoie, E. J. Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors. J. Med. Chem. 1995, 38, 3638-3644.
68. Wang, J. C. DNA Topoisomerases. Annu. Rev. Biochem. 1985, 54, 665-697.
69. Dodds, E. C.; Goldberg, L.; Lawson, W.; Robinson, R. Estrogenic Activity of Certain Synthetic Compounds. Nature (London) 1938, 141, 247-248.
70. Walton, E.; Brownlee, G. Isomers of Stilboestrol and its Esters. Nature 1943, 151, 305-306.
71. Blanchard, E. W.; Stuart, A. H.; Tallman, R. C. Studies On A New Series of Synthetic Estrogenic Substances. Endocrinology 1943, 32, 307.
72. Baker, B. R. Some Analogs of Hexestrol. J. Am. Chem. Soc. 1943, 65, 1572.
73. Macchia, B.; Balsamo, A.; Lapucci, A.; Martinelli, A.; Macchia, F.; Breschi, M. C.; Fantoni, B.; Martinotti, E. An Interdisciplinary Approach to the Design of New Structures Active at the β-Adrenergic Receptor. Aliphatic Oxime Ether Derivatives. J. Med. Chem. 1985, 28, 153-160.
74. Balsamo, A.; Breschi, M. C.; Chini, M.; Doniano, P.; Giannaccini, G.; Lucacchini, A.; Macchia, B.;Macchia, M.; Manera, C.; Martinelli, A.; Martini, C.; Martinotti, E.; Nieri, P.; Rosello, A. Conformationally Restrained β-Blocking Oxime Ethers: Synthesis and β-Adrenergic Properties of Diasteroisomeric Anti and Syn (2-(5′-Isoxazolidinyl)-ethanolamines. Eur. J. Med. Chem. 1992, 27, 751-764.
75. Balsamo, A.; Dell'Omodarme, G.; Lapucci, A.; Macchia, M.; Orlandini, E.; Ferni, G.; Pinza, M. Synthesis and β-Adrenergic Activity of New Completely Aliphatic β-(Methyleneaminoxy)-propanolamine Derivatives. XVIIth National Meeting of the Italian Chemical Society, Genova, 1992.
76. Triggle, D. J. In Burger's Medicinal Chemistry; Wolff, M. E., Ed.; Wiley: New York, 1981; Chapter 41.
77. Weiner, N. In The Pharmacological Basis of Therapeutics; Gilman, A., Goodman, L. S., Eds.; Macmillan: New York, 1980; Chapters 8 and 9.
78. Petrongolo, C.: Macchia, B.; Macchia, F.; Martinelli, A. J. Molecular Orbital Studies on the Mechanism of Drug-Receptor Interaction. 2. β-Adrenergic Drugs. An Approach to Explain the Role of the Aromatic Moiety. J. Med. Chem. 1977, 20, 1645-1653.
79. Macchia, B.; Macchia, F.; Martinelli, A. MO Studies on the Mechanism of Drug-Receptor Interaction. 3. Adrenergic Drug Reactivity of Tazolol. Eur. J. Med. Chem. 1980, 15, 515-520.
80. Macchia, B.; Balsamo, A.; Lapucci, A.; Macchia, F.; Martinelli, A.; Nencetti, S.; Orlandini, E.; Baldacci, M.; Mengozzi, G.; Soldani, G.; Domiano, P. Molecular Design, Synthesis, and Antiinflammatory Activity of a Series of β-Aminoxypropionic Acids. J. Med. Chem. 1990, 33, 1423-1430.
81. Balsamo, A.; Broccali, G.; Lapucci, A.; Macchia, B.; Macchia, F.; Orlandini, E.; Rossello, A. Synthesis and Antimicrobial Properties of Substituted β-Aminoxypropionyl Penicillins and Cephalosporins. J. Med. Chem. 1989, 32, 1398-1401.
82. Balsamo, A.; Lapucci, A.; Macchia, M.; Martinelli, A.; Nencetti, S.; Rossello, A.; Cristina, T. 2-(Methyleneaminoxy)methylmorpholine Derivatives. Synthesis and Antidepressant Activity Farmaco 1994, 49, 77-82.
83. Macchia, B.; Balsamo, A.; Breschi, M. C.; Chiellini, G.; Macchia, M.; Martinelli, A.; Martini, C.; Nardini,C.; Nencetti, S.; Rossello, A.; Scatizzi, R. The [(Methyloxy)imino]methyl Moiety as a Bioisoster of Aryl. A Novel Class of Completely Aliphatic β-Adrenergic Receptor Antagonists. J. Med. Chem. 1994, 37, 1518-1525.
84. 1 Receptor. J. Med Chem. 1994, 37, 1269-1274.
85. 1 Antagonists Derived from L-Tryptophan. J. Med. Chem. 1995, 38, 934-941.
86. 1 Antagonists: Conformationally Constrained Heterocyclic Bioisosteres Of The Ester Linkage. J. Med. Chem. 1995, 38, 923-933.
87. Freedman, S. B.; Harley, E. A.; Patel, S.; Newberry, N. R.; Gilbert, M. J.; McKnight, A. T.; Tang, J. K.; Maguire, J. J.; Mundunkotuwa, N. T.; Baker, R.; Street, L. J.; MacLeod, A. M.; Saunders, J.; Iversen, L. L. A Novel Series of Nonquaternary Oxadiazoles Acting as Full Agonists at Muscarinic Receptors. Br. J. Pharmacol. 1990, 101, 575-580.
88. Eglen, R. M.; Harris, G. C.; Ford, A. P. D. W.; Wong, E. H. F.; Pfister, J. R.; Whiting, R. L. The Action of (±)L-660,863 [(+)3-(3-amino-1,2,4-oxadiazole-5-yl)quinuclidine] at Muscarinic Receptor Subtypes In vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 1992, 345, 375-381.
89. Sauerberg, P.; Kindtler, J. W.; Nielsen, L.; Sheardown, M. J.; Honoré, T. Muscarinic Cholinergic Agonists and Antagonists of the 3-(3-Alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine Type. Synthesis and Structure-Activity Relationships. J. Med. Chem. 1991, 34, 687-692.
90. Saunders, J.; Cassidy, M.; Freedman, S. B.; Harley, E. A.; Iversen, L. L.; Kneen, C.; MacLeod, A. M.; Merchant, K.; Snow, R. J.;Baker, R. Novel Quinuclidine-Based Ligands For The Muscarinic Cholinergic Receptor. J. Med. Chem. 1990, 33, 1128-1138.
91. Street, L. J.; Baker, R.; Book, T.; Kneen, C. O.; MacLeod, A. M.; Merchant, K. J.; Showell, G. A.; Saunders, J.; Herbert, R. H.; Freedman, S. B.; Harley, E. A. Synthesis and Biological Activity of 1,2,4-oxadiazoles derivatives: Highly Potent and Efficacious Agonists for Cortical Muscarinic Receptors. J. Med. Chem. 1990, 33, 2690-2697.
92. Freedman, S. B.; Harley, E. A.; Marwood, R. S.; Patel, S. In vivo Characterization of Novel Efficacious Muscarinic Receptor Agonists. Eur. J. Pharm. 1990, 187, 193-199.
93. Sauerberg, P.; Larsen, J.-J.; Falch, E.; Krogsgaard-Larsen, P. A Novel Class of Conformationally Restricted Heterocyclic Muscarinic Agonists. J. Med. Chem. 1986, 29, 1004-1009.
94. Krogsgaard-Larsen, P.; Pedersen, H.; Falch, E. Eur. Pat. Appl. 336 555, 11 Oct 1989.
95. 1 Selective Muscarinic Agonists. Synthesis and Structure-Activity Relationships of 3-(1,2,5-Thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem. 1992, 35, 2274-2283.
96. Moltzen, E. K.; Pedersen, H.; Bøgesø, K. P.; Meier, E.; Frederiksen, K.; Sánchez, C.; Lembøl, L. H. Bioisosteres of Arecoline: 1,2,3,6-Tetrahydro-5-pyridyl-Substituted and 3-Piperidyl-Substituted Derivatives of Tetrazoles and 1,2,3-Triazoles. Synthesis and Muscarinic Activity. J. Med. Chem. 1994, 37, 4085-4099.
97. MacDonald, R. L.; Olsen, R. W. GABAA Receptor Channels. Annu. Rev. Neurosci. 1994, 17, 569-602.
98. Bonanno, G.; Raiteri, M. Multiple GABAB Receptors. Trends Pharmacol. Sci. 1993, 14, 259-261.
99. Krogsgaard-Larsen, P.; Frølund, B.; Jørgensen, F. S.; Schousboe, A. GABAA Receptor Agonists, Partial Agonists and Antagonists. Design and Therapeutic Prospects. J. Med. Chem. 1994, 37, 2489-2505.
100. Krogsgaard-Larsen, P.; Johnston, G. A. R.; Curtis, D. R.; Game, C. J. A.; McCulloch, R. M. Structure and Biological Activity of a Series of Conformationally Restricted Analogues of GABA. J. Neurochem. 1975, 25, 803-809.
101. Krogsgaard-Larsen, P.; Hjeds, H.; Curtis, D. R.; Lodge, D.; Johnston, G. A. R. Dihydromuscimol, Thiomuscimol and Related Heterocyclic Compounds as GABA Analogues. J. Neurochem. 1979, 32, 1717-1724.
102. Krogsgaard-Larsen, P.; Falch, E.; Hjeds, H. Heterocyclic Analogues of GABA: Chemistry, MolecularPharmacology and Therapeutic Aspects. Prog. Med. Chem. 1985, 22, 67-120.
103. Krogsgaard-Larsen, P.; Hjeds, H.; Falch, E.; Jørgensen, F. S.; Nielsen, L. Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure-Activity Relationships and Therapeutic Potential. Adv. Drug. Res. 1988, 17, 381-456.
104. Krogsgaard-Larsen, P.; Johnston, G. A. R.; Lodge, D.; Curtis, D. R. A New Class of GABA Agonist. Nature (London) 1977, 268, 53-55.
105. Krogsgaard-Larsen, P.; Mikkelsen, H.; Jacobsen, P.; Falch, E.; Curtis, D. R.; Peet, M. J.; Leah, J. D. 4,5,6,7-Tetrahydroisothiazolo[5,4-c]pyridin-3-ol and Related Analogues of THIP. Synthesis and Biological Activity. J. Med. Chem. 1983, 26, 895-900.
106. Arnt, J.; Krogsgaard-Larsen, P. GABA Agonists and Potential Antagonists Related to Muscimol. Brain Res. 1979, 177, 395-400.
107. Byberg, J. R.; Labouta, I. M.; Falch, E.; Hjeds, H.; Krogsgaard-Larsen, P.; Curtis, D. R.; Gynther, B. D. Synthesis And Biological Activity Of A GABA-A Agonist Which Has No Effect On Benzodiazepine Binding And Structurally Related Glycine Antagonists. Drug Des. Delivery 1987, 1, 261-274.
108. Kristiansen, U.; Lambert, J. D. C.; Falch, E.; Krogsgaard-Larsen, P. Electrophysiological Studies of The GABAA Receptor Ligand, 4-PIOL, on Cultured Hippocampal Neurones. Br. J. Pharmacol. 1991, 104, 85-90.
109. A Agonist and a Glycine Antagonist Related to the GABAA Agonist, THIP. Drug Des. Discovery 1993, 10, 213-229.
110. Frølund, B.; Kristiansen, U.; Brehm, L.; Hansen, A. B.; Krogsgaard-Larsen, P.; Falch, E. Partial GABAA Receptor Agonists. Synthesis and in Vitro Pharmacology of a Series of Nonannulated Analogs of 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol. J. Med. Chem. 1995, 38, 3287-3296.
111. 2 Analogues Possessing Cyclic Amino Acid Residues at the C-Terminal Position. J. Med. Chem. 1986, 29, 2100-2104.
112. Chiu, S.; Paulose, C. S.; Mishra, R. K. Effect of L-Proyl-L-Leucyl-Glycinamide (PLG) on Neuroleptic-Induced Catalepsy and Dopamine/Neuroleptic Receptor Bindings. Peptides 1981, 2, 105-111.
113. 2 Receptor: Evidence for Modulation of Agonist Affinity States in Bovine Striatal Membranes. J. Neurochem. 1988, 50, 960-968.
114. 2. J. Med. Chem. 1988, 31, 1430-1436.
115. 2. J. Med. Chem. 1993, 36, 256-263.
116. 2 J. Med. Chem. 1993, 36, 2356-2361.
117. Hansch, C.; Leo, L. In Exploring QSAR. Fundamentals and Applications in Chemistry and Biology; Heller, S. R., Cons. Ed.; American Chemical Society: Washington, 1995; Chapter 13.
118. Larsen, A. A.; Lish, P. M. A New Bioisostere: Alkylsulphona-midophenethanolamines Nature 1964, 203, 1283.
119. Larsen, A. A.; Gould, W. A.; Roth, H. R.; Comer, W. T.; Uloth, R. H.; Dungan, K. W.; Lish, P. M. Sulfonanilides. II. Analogs of Catecholamines. J. Med. Chem. 1967, 10, 462-472.
120. Kaiser, C.; Colella, D. F.; Schwartz, M. S.; Garvey, E.; Wardell, J. R. Adrenergic Agents. 1. Synthesis and Potential -Adrenergic Agonist Activity of Some Catecholamine Analogs Bearing a Substituted Amino Functionality in the Meta Position. J. Med. Chem. 1974, 17, 49-57.
121. Ross, S. B. In Vivo Inactivation of Catecholamines in Mice. Acta Pharmacol. Toxicol. 1963, 20, 267.
122. Clark, R. D.; Caroon, J. M.; Isaac, N. E.; McClelland, D. L., Michel, A. D.; Petty, T. A.; Rosenkranz, R. P.; Waterbury, L. D. Synthesis and Pharmacological Evaluation of N,N-di-n-Propyldopamine Cogeners Containing Phenolic Bioisosteres. J. Pharm. Sci. 1987, 76, 411-415.
123. Seiler, M. P.; Markstein, R. In Vivo Regulation of Muscarinic Cholinergic Receptors in Embryonic Chick Brain. Mol. Pharmacol. 1982, 22, 281-289.
124. McDermed, J. D.; McKenzie, G. M.; Freeman, H. S. Synthesis and Dopaminergic Activity of (±)-, (+)-, and (-)-2-Dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthlene. J. Med. Chem. 1976, 19, 547-549.
125. Tedesco, J. T.; Seeman, P.; McDermed, J. D. The Conformation of Dopamine At Its Receptor: Binding of Mono-hydroxy-2-aminotetralin Enantiomers and Positional Isomers. Mol. Pharmacol. 1979, 16, 369-381.
126. Asselin, A.; Humber, L.; Voith, K.; Metcalf, G. Drug Design via Pharmacophore Identification. Dopaminergic Activity of 3H-benz[e]indol-8-amines And Their Mode of Interaction with the Dopamine Receptor. J. Med. Chem. 1986, 29, 648-654.
127. Rosei, E. A.; Fraser, R.; Morton, J. J.; Brown, J. J.; Lever, A. F.; Robertson, J. I. S.; Trust, P. M. Labetalol, an α- and β-adrenergic Blocking Drug in the Treatment of Hypertension. Am. Heart J. 1977, 93, 124-125.
128. Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Labetalol: A Review of its Pharmacology and Therapeutic Use in Hypertension. Drugs 1978, 15, 251-270.
129. Asselin, A. A.; Humber, L. G.; Crosilla, D.; Oshiro, G.; Wojdan, A.; Grimes, D.; Heaslip, R. J.; Rimele, T. J.; Shaw, C. IndolePhenol Bioisosterism. Synthesis and Antihypertensive Activity of a Pyrrolo Analogue of Labetalol. J. Med. Chem. 1986, 29, 1009-1015.
130. Hashiguchi, H.; Takahashi, H. Inhibition of Two Copper-Containing Enzymes, Tyrosinase and Dopamine β-hydroxylase by L-Mimosine. Mol. Pharmacol. 1977, 13, 362-367.
131. Inoue, S.; Shamura, T.; Tsurvoka, T.; Ogawa, Y.; Wanatabe, H.; Yoshidea, J.; Nuda, T. L-β-(5-Hydroxy-2-pyridyl)-alanine and L-β-(3-Hydroxyureido)-alanine from Steptomyces. Chem. Pharm. Bull. 1975, 23, 2669-2677.
132. Norton, S. J.; Sanders, E. DL-4,5-Dihydroxy-2-pyridylalanine, An Analog of 3,4-Dihydroxyphenylalanine. J. Med. Chem. 1967, 10, 961-963.
133. Harris, R. N. L.; Teitel, T. Potential Wool Growth Inhibitors. 2(1H)-Pyridone Analogs of Mimosine. Austr. J. Chem. 1977, 30, 649-655.
134. Hansch, C.; Leo, A. In Substituent Constants For Correlation Analysis in Chemistry and Biology; Wiley Interscience: New York, 1979; Chapter 6.
135. Gapinski, D. M.; Mallett, B. E.; Froelich, L. L.; Jackson, W. T. Benzophenone Dicarboxylic Acid Antagonists of Leukotriene B4. 1. Structure-Activity Relationships of the Benzophenone Nucleus. J. Med. Chem. 1990, 33, 2798-2807.
136. 4-like Material in Scale of Psoriatic Skin Lesions. Br. J. Pharmacol. 1984, 83, 313-317.
137. Brain, S. D.; Camp, R.; Dowd, P.; Black, A. K.; Greaves. M. J. The Release of Leukotriene B4-like Material in Biologically Active Amounts from the Lesional Skin of Patients with Psoriasis. J. Invest. Dermatol. 1984, 83, 70-73.
138. Sharon, P.; Stentson, W. F. Enhanced Synthesis of Leukotriene B4 by Colonic Mucosa in Inflammatory Bowel Disease. Gastroenterology 1984, 86, 453-460.
139. Peskar, B. M.; Dreyling, K. W.; May, B.; Thieves, M.; Morgenroth, K.; Goebell, H.; Peskar, B. A. Increased Formation of Leukotriene B4 and Sulphidopeptide-leukotrienes by Rectal Mucosa of Patients' with Crohn's Disease and Ulcerative Colitis. Gut 1985, 26, A542.
140. Calhoun, W.; Carlson, R. P.; Crossley, R.; Datko, L. J.; Dietrich, S.; Heatherington, K.; Marshall, L. A.; Meade, P. J.; Opalko, A.; Shepherd, R. G. Synthesis and Anti-inflammatory Activity of Certain 5,6,7,8-Tetrahydroisoquinolines and Related Compounds. J. Med. Chem. 1995, 38, 1473-1481.
141. Chihiro, M.; Nagamoto, H.; Takemura, I.; Kitano, K.; Komatsu, H.; Sekiguchi, K.; Tabusa, F.; Mori, T.; Tominaga, M.; Yabuuchi, Y. Novel Thiazole Derivatives as Inhibitors of Supreoxide Production by Human Neutrophils: Synthesis and Structure-Activity Relationships. J. Med. Chem. 1995, 38, 353-358.
142. Hanna, N. B.; Bhattacharya, B. K.; Robins, R. K.; Avery, T. L.; Revankar, G. R. Sulfinosine Cogeners: Synthesis and Anti-tumor Activity in Mice of Certain N9-Alkyl Purines and Purine Ribonucleosides. J. Med. Chem. 1994, 37, 177-183.
143. Shah, S. K.; Brause, K. A.; Chandler, G. O.; Finke, P. E.; Ashe, B. M.; Weston, H.; Knight, W. B.; Maycock, A. L.; Doherty, J. B. Inhibition of Human Leukocyte Elastase. 3. Synthesis and Activity of 3′-Substituted Cephalosporins. J. Med. Chem. 1990, 33, 2529-2535.
144. Rizzi, J. P.; Schnur, R. C.; Hutson, N. J.; Kraus, K. G.; Kelbaugh, P. R. Rotationally Restricted Mimics of Rigid Molecules: Non-spirocyclic Hydantoin Aldose Reductase Inhibitors. J. Med. Chem. 1989, 32, 1208-1213.
145. Muchowski, J. M.; Galeazzi, E.; Greenhouse, R.; Guzman, A.; Perez, V.; Ackerman, N.; Ballaron, S. A.; Roviti, J. R.; Tomolonis, A. J.;Young, J. M.; Rooks, W. H. Synthesis and Anti-inflammatory and Analgesic Activity of 5-Aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo [1,2-a] pyrrole-1-carboxylic Acids and 1-Methyl-4-(methylthio)-5-aroylpyrrole-2-acetic Acids. J. Med. Chem. 1989, 32, 1202-1207.
146. Sarges, R.; Peterson, M. J. Sorbinil: A Member of the Novel Class of Spirohydantoin Aldose Reductase Inhibitors. Metabolism 1986, 35 (4 Suppl. 1), 101-104.
147. Sarges, R.; Schnur, R. C.; Belletire, J. L.; Peterson, M. J. Spiro Hydantoin Aldose Reductase Inhibitors. J. Med. Chem. 1988, 31, 230-243.
148. DeFronzo, R. A. The Triumvirate: Cell, Muscle, Liver: A Collusion Responsible for NIDDM. Diabetes 1988, 37, 667-687.
149. Turner, R. C.; Matthews, D. R.; Clark, A.; O'Rahilly, S.; Rudenski, A. S. Pathogenesis of NIDDM- a Disease of Deficient Insulin Secretion. Baillieres Clin. Endocrinol. Metab. 1988, 2, 327-342.
150. Goldman, J. M. Oral Hypoglycemic Agents: an Update of Sulfonylureas. Drugs Today 1989, 25, 689-695.
151. Kolterman, O. G.; Prince, M. J.; Olefsky, J. M. Insulin Dependent Diabetes Mellitus: Impact of Sulfonylureas agents in Vivo and in Vitro. Am. J. Med. 1983, 74 (Suppl. 1A), 82-101.
152. Dow, R. L.; Bechle, B. M.; Chou, T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-diones as Potent Hypoglycemic Agents. J. Med. Chem. 1991, 34, 1538-1544.
153. Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel thaizolidine-2,4-diones as Potent Euglycemic Agents. J. Med. Chem. 1992, 35, 1853-1864.
154. Yee, Y. K.; Bernstein, P. R.; Adams, E. J.; Brown, F. J.; Cronk, L. A.; Hebbel, K. C.; Vacek, E. P.; Krell, R. D.; Snyder, D. W. A Novel Series of Selective Leukotriene Antagonists: Exploration and Optimazation of the Acidic Region in 1,6-Disubstituted Indoles and Indazoles. J. Med. Chem. 1990, 33, 2437-2451.
155. Domagk, G. Chemotherapy of Bacterial Infections. Deut. Med. Wochschr. 1935, 61, 250-3.
156. Tréfouel, J.; Trefouel, J. Mme.; Nitti, F.; Bovet, D. Action of p-aminophenylsulfamide in Experimental Streptococcus Infections of Mice and Rabbits. Compt. Rend. Soc. Bio. 1935, 720, 756-758.
157. Anand, N. In Burger's Medicinal Chemistry, 4th ed.; Wolff, M. E., Ed.; Wiley-Interscience: New York, 1979; Part II, Chapter 13.
158. Bock, M. G.; DiPardo, R. M.; Mellin, E. C.; Newton, R. C.; Verber, D. F.; Freedman, S. B.; Smith, A. J.; Patel, S.; Kemp, J. A.; Marshall, G. R.; Fletcher, A. E.; Chapman, K. L.; Anderson, P. S.; Freidinger, R. M. Second-Generation Benzodiazepine CCK-B Antagonists. Development of Subnanomolar Analogs with Selectivity and Water Solubility. J. Med. Chem. 1994, 37, 722-724.
159. Hammarstrom, S.; Murphy, R. C.; Clark, D. A.; Mioskowski, C.; Corey, E. J. Structure of Leukotriene C. Identification of the Amino Acid Part. Biochem. Biophys. Res. Commun. 1979, 91, 1266.
160. Schaaf, T. K.; Hess, H. J. Synthesis and Biological Activity of Carboxyl-Terminus Modified Prostaglandin Analogues. J. Med. Chem. 1979, 22, 1340.
161. Guida, W. C.; Elliott, R. D.; Thomas, H. J.; Secrist III, J. A.; Babu, Y. S.; Bugg, C. E.; Erion, M. D.; Ealick, S. E.; Montgomery, J. A. Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimetics. J. Med. Chem. 1994, 37, 1109-1114.
162. Spatola, A. F. In Chemistry and Biochemistry of Amino Acids, Peptides and Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; Vol. VII, pp 267-357.
163. Giannis, A.; Kolter, T. Peptidomimetics for Receptor Ligands-Discovery, Development, and Medical Perspectives. Angew. Chem., Int. Ed. Engl. 1993, 32, 1244-1267.
164. Boyd, S. A.; Fung, A. K. L.; Baker, W. R.; Mantei, R. A.; Stein, H. H.; Cohen, J.; Barlow, J. L.; Klinghofer, V.; Wessale, J. L.; Verburg, K. M.; Polakowski, J. S.; Adler, A. L.; Calzadilla, S. V.; Kovar, P.; Yao, Z.; Hutchins, C. W.; Denissen, J. F.; Grabowski, B. A.; Cepa, S.; Hoffman, D. J.; Garren, K. W.; Kleinert, H. D. Nonpeptide Renin Inhibitors with Good Intraduodenal Bioavailability and Efficacy in Dog. J. Med. Chem. 1994, 37, 2991-3007.
165. Andersen, K. E.; Jørgensen, A. S.; Braestrup, C. Oxadiazoles as Bioisosteric Transformations of Carboxylic Functionalities. Part I. Eur. J. Med. Chem. 1994, 29, 393-399.
166. Carroll, F. I.; Gray, J. L.; Abraham, P.; Kuzemko, M. A.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. 3-Aryl-2-(3′-substituted-1′,2′,4′-oxadiazol-5′-yl) tropane Analogues of Cocaine: Affinities at the Cocaine Binding Site at the Dopamine, Serotonin, and Norepinephrine Transporters. J. Med. Chem. 1993, 36, 2886-2890.
167. 1D Receptors. J. Med. Chem. 1993, 36, 1529-1538.
168. 1 Musearinic Receptor Agonists. J. Med. Chem. 1993, 36, 842-847.
169. Adelstein, G. W.; Yen, C. H.; Dajani, E. Z.; Bianchi, R. G. 3,3-Diphenyl-3-(2-alkyl-1,3,4-oxadiazol-5-yl)propylcycloalkylamines, A Novel Series of Antidiarrheal Agents J. Med. Chem. 1976, 19, 1221-1225.
170. Tully, W. R.; Gardner, C. R.; Gillespie, R. J.; Westwood, R. 2-(Oxadiazolyl)- and 2-(Thiazolyl)imidazo[1,2-a]pyrimidines as Agonists and Inverse Agonists at Benzodiazepine Receptors. J. Med. Chem. 1991, 34, 2060-2067.
171. Orlek, B. S.; Blaney, F. E.; Brown, F.; Clark, M. S. G.; Hadley, M. S.; Hatcher, J.; Riley, G. J.; Rosenberg, H. E.; Wadsworth, H. J.; Wyman, P. Comparison of Azabicyclic Esters and Oxadiazoles as Ligands for the Muscarinic Receptor. J. Med. Chem 1991, 34, 2726-2735.
172. 2′ Amide Bond Isosteres. Bioorg. Med. Chem. Lett. 1994, 4, 2441-2446.
173. Kim, B. H.; Chung, Y. J.; Keum, G.; Kim, J.; Kim, K. A New Peptide Bond Surrogate: 2-Isoxazoline in Pseudodipeptide Chemistry. Tetrahedron Lett. 1992, 33, 6811-6814.
174. Jones, C. F. R.; Ward, G. J. Amide Bond Isosteres: Imidazolines in Pseudopeptide Chemistry. Tetrahedron Lett. 1988, 29, 3853-3856.
175. Clercq, E. D. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections J. Med. Chem. 1995, 38, 2491-2517.
176. Suckling, K. E.; Stange, E. F. Role of Acyl-CoA: Cholesterol Acyl Transferase in Cellular Cholesterol Metabolism. J. Lipid Res. 1985, 26, 647-671.
177. Sliskovic, D. R.; White, A. D. Therapeutic Potential of ACAT Inhibitors as Lipid Lowering and Anti-atherosclerotic Agents. Trends Pharmacol. Sci. 1991, 11, 194-199.
178. Roark, W. H.; Roth, B. D.; Holmes, A.; Trivedi, B. K.; Kieft, K. A.; Essenburg, A. D.; Krause, B. R.; Stanfield, R. L. Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). 2. Modification of Fatty Acid Anilide ACAT Inhibitors: Bioisosteric Replacement of the Amide Bond. J. Med. Chem. 1993, 36, 1662-1668.
179. Kagechika, H.; Himi, T.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Retinobenzoic Acids. 4. Conformation of Aromatic Amides with Retinoidal Activity. Importance of trans-Amide Structure for the Activity. J. Med. Chem. 1989, 32, 2292-2296.
180. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. New Type Inducers of Differentiation of Human HL-60 Promyelocytic Leukemia Cells. Terephthalic Anilides. Chem. Pharm. Bull. 1984, 32, 4209-4212.
181. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Himi, T.; Shudo, K. Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity. J. Med. Chem. 1988, 31, 2182-2192.
182. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Differentiation Inducers of Human Promyelocytic Leukemia Cells HL-60. Phenylcarbamoylbenzoic Acids and Polyene Amides. Chem. Pharm. Bull. 1986, 34, 2275-2278.
183. Shudo, K.; Kagechika, H.; Kawachi, E.; Hashimoto, Y. Chalcone Carboxylic Acids. Potent Differentiation Inducers of Human Promyelocytic Cells HL-60. Chem. Pharm. Bull. 1985, 33, 404-407.
184. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Retinobenzoic Acids. 2. Structure-Activity Relationships of Chalcone-4-carboxylie Acids and Flavone-4′-carboxylic Acids. J. Med. Chem. 1989, 32, 834-840.
185. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Differentiation Inducers of Human Promyelocytic Leukemia Cells HL-60. Azobenzenecarboxylic Acids and Stilbenecarboxylic Acids. Chem. Pharm. Bull. 1985, 33, 5597-5600.
186. 2-Receptor Antagonists with Potent Gastroprotective Effects Against Nonsteroidal Antiinflammatory Drug-Induced Injury. J. Med. Chem. 1994, 37, 57-66.
187. Orr, F. G.; Musso, D. L.; Boswell, G. E.; Kelley, J. L.; Joyner, S. S.; Davis, S. T.; Baccanari, D. P. Inhibition of Uridine Phosphorylase: Synthesis and Structure-Activity Relationships of Aryl-Substituted 5-Benzyluracils and 1-[(2-Hydroxyethoxy)-methyl]-5-benzyluracils. J. Med. Chem. 1995, 38, 3850-3856.
188. el Kouni, M. H.; el Kouni, M. M.; Naguib, F. M. N. Differences in Activities and Substrate Specificity of Human and Murine Pyrimidine Nucleoside Phosphorylases: Implications for Chemotherapy with 5-Fluoropyrimidines. Cancer Res. 1993, 53, 3687-3693.
189. Chu, M. Y. W.; Naguib, F. M. N.; Iltzsch, M. H.; el Kouni, M. H.; Chu, S. H.; Cha, S.; Calabresi, P. Potentiation of 5-Fluoro-2′-Deoxyuridine Antineoplastic Activity By the Uridine Phosphorylase Inhibitors Benzylacyclouridine and Benzyloxybenzyl-acyclouridine. Cancer Res. 1984, 44, 1852-1856.
190. Tokarski, J. S.; Hopfinger, A. J. Three-Dimensional Molecular Shape Analysis-Quantitative Structure-Activity Relationship of a Series of Cholecystokinin-A receptor Antagonists. J. Med. Chem. 1994, 37, 3639-3654.
191. Gertz, B. J. Potential Clinical Applications of a CCK Antagonist. In Neurol. Neurobiol., 47; Wang, R. Y., Schoenfeld, R., Eds.; Alan R. Liss: New York, 1988; pp 327-342.